Zobrazeno 101 - 110
of 1 548
pro vyhledávání: ''
Autor:
Finn Cilius Nielsen, Olga Oestrup, Ulrik Lassen, Hans Skovgaard Poulsen, Petra Hamerlik, Jane Skjøth-Rasmussen, Christina Westmose Yde, Dorte Schou Noeroexe
Publikováno v:
Cancer Research. 81:444-444
Introduction: Glioblastoma (GBM) is a heterogenous cancer with a high degree of intratumoral subclonality. We foresee that future treatment will be a combination of non-targeted and targeted therapies against molecular features of each patient. In or
Autor:
Han Zhang, Dayong Zhai, Herve Aloysius, Evan Rogers, Xin Zhang, Ana Parra, Vivian Nguyen, Ung Jane, Dong Lee, Wei Deng, Maria Barrera, Jessica Cowell, Brion W. Murray
Publikováno v:
Cancer Research. 81:1469-1469
Three generations of ALK inhibitors are approved for the treatment of ALK+ NSCLC but their efficacy is often limited by ALK resistance mutations. The solvent front mutation G1202R and gatekeeper mutation L1196M are major resistance mechanisms to the
Autor:
Vishnu C. Damalanka, James W. Janetka, Lidija Klampfer, Robert J. Coffey, Galina Bogatcheva, Ramona Graves-Deal, Bhuminder Singh
Publikováno v:
Cancer Research. 81:1084-1084
Using a novel 3D culture system, we previously showed that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to cetuximab resistance in colorectal cancer (CRC) cells. CC derived from HCA-7 cells were sensitive to cetuximab, where
Publikováno v:
Cancer Research. 81:1353-1353
Background: RAS mutations are found in nearly one third of patients with cancer. As part of the Ras-Raf-MEK-ERK pathway, RAS mutations lead to uninhibited cell growth, proliferation, and survival. KRAS mutations account for a large majority of RAS mu
Autor:
Lysiane Huber, David Anthony Barda, Youyan Zhang, Sheng-Bin Peng, Xueqian Gong, Junpeng Xiao, Deqi Guo, Jing Wang, Carmen Curtis, Bradley L. Ackermann, Wayne P. Bocchinfuso, Danalyn Manglicmot, Gregory P. Donoho, Paul D. Cornwell, Ryan J. Linder, Chong Si, Lee J. Burns, Michael J. Chalmers, Xi Lin, Denis J. McCann, Henry James Robert, Robert D. Van Horn, Serge Louis Boulet, Melbert-Brian D. Saflor, John Strelow, Lian Zhou
Publikováno v:
Cancer Research. 81:1259-1259
KRAS-G12C is an important oncogenic mutation in patients with NSCLC, CRC, and other cancer types. Currently, there are no FDA-approved KRAS-G12C inhibitors, and those in clinical development have relatively modest activity compared to other approved
Autor:
Feng Zhou, Kaixiang Zhang, Yu Guo, Yuanbao Li, Douglas D. Fang, Jing Deng, Lin Zhang, Jie Chen, Dajun Yang, Fan Luo, Yifan Zhai, Xiaojing Huang
Publikováno v:
Cancer Research. 81:984-984
Current targeted therapies such as VEGFR inhibitor sunitinib and mTOR inhibitor everolimus extend progression-free survival (PFS) in patients with Grade 1 (G1) and G2 neuroendocrine tumors (NET), but the objective response rate remains low. The media
Publikováno v:
Cancer Research. 81:1431-1431
Osimeritinib (OR), a Tyrosine Kinase Inhibitor is a first-line therapy in EGFR-mutant NSCLC patients. Resistance to OR treatment may occur due to acquired C797S mutations, MET amplifications and ALK rearrangements and other mechanisms not clearly def
Autor:
Daniel I. Isaac, Ryan Ramaekers, Mark Erlander, Manish R. Sharma, Lawrence Mendelsohn, Maya Ridinger
Publikováno v:
Cancer Research. 81:425-425
Introduction: Chemotherapy in combination with targeted agents are standard-of-care options for first and second-line treatment of metastatic colorectal cancer (mCRC) patients. Second-line treatment of KRAS-mutated mCRC confers a dismal patient outco
Autor:
Tamika Mitchell, Irmina Diala, Vidyalakshmi Sethunath, Ragini Mistry, Rachel Schiff, Fabio Stossi, Sarmistha Nanda, Mothaffar F. Rimawi, Meenakshi Anurag, Martin Shea, Chia Chia Liu, Alshad S. Lalani, Michael A. Mancini, C. Kent Osborne, Sreyashree Bose, Jamunarani Veeraraghavan
Publikováno v:
Cancer Research. 81:1077-1077
The role of HER2 and PIK3CA mutations in anti-HER2 resistance is gaining more importance in HER2-positive (+) breast cancer. We recently reported that acquired resistance to lapatinib (Lap)-containing regimens is mediated by HER2 L755S, which could b
Autor:
Tonghui Ma, Yanling Niu, Chengyun Geng, Sheng Yang, Xiaoyan Zhang, Xiaohui He, Kan Liu, Xin Zhang
Publikováno v:
Cancer Research. 81:1199-1199
Introduction: Although the contribution of mosaicism to tumorigenesis emerges during embryonic development, it is a very rare phenomenon in tumor patients. Only a few mosaic RAS mutations have been identified, such as NRAS G12D, NRAS G12S, KRAS G12D.